Bioretec Ltd. has recruited Jordy Winters to be vice president of Sales Outside U.S. (OUS; Europe and Rest of the World) and management team member. Winters will spearhead the company’s international commercial strategy, advancing its expansion into key markets outside the United States and driving revenue growth.

“We are delighted to welcome Jordy Winters to our executive team,” Bioretec CEO Sarah van Hellenberg Hubar-Fisher said. “With nearly two decades of proven excellence in global orthopedic commercial leadership, his expertise and international perspective will be instrumental as we continue to expand Bioretec’s impact outside the U.S.”

Winters has extensive sales leadership experience from Johnson & Johnson MedTech and DePuy Synthes, with a strong record of driving commercial adoption and building high-performing  teams. Most recently, he was spine lead EMEA, driving regional strategy and growth. His earlier positions included business lead DePuy Synthes, sales director Orthopaedics, and leadership roles in Joint Reconstruction, Spine, and Trauma.

From starting his career as a sales consultant to leading large-scale teams across EMEA, Winters has consistently demonstrated a strong commitment to advancing orthopedics and spine care solutions that positively impact patients’ lives. His appointment strengthens Bioretec’s leadership as the company scales operations and seizes opportunities in orthopedics with its Activa absorbable polymer platform and RemeOs absorbable magnesium alloy technology, executives noted.

Bioretec’s Activa product line features fully bioabsorbable orthopedic implants made from a proprietary, self-reinforced PLGA polymer. These implants deliver secure fixation through patented innovations and naturally degrade in approximately two years, eliminating the need for costly and invasive removal surgeries while supporting optimal bone regeneration. Activa products are both CE marked, and cleared by the U.S. Food and Drug Administration (FDA) for a wide range of indications in adults and children.

The company’s RemeOs product line is based on a high-performance magnesium alloy and hybrid composite, introducing a new generation of strong absorbable materials for enhanced surgical outcomes. The RemeOs implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The FDA authorized the first RemeOs product in March 2023, and CE mark approval followed in January 2025.

“Bioretec is entering an important phase of growth, with increasing demand for innovative, sustainable solutions in orthopedics,” Winters stated. “I look forward to driving the company’s international commercial success and forging strategic partnerships that deliver value to patients, surgeons, and shareholders worldwide.”

In parallel, former OUS Sales Vice President Rami Ojala will transition into the newly created role of head of Global Medical Education. In this position, Ojala will lead efforts to advance surgeon training programs, develop educational initiatives, and support clinical adoption of Bioretec’s technologies worldwide.

Bioretec is a globally operating Finnish medical device developer of fully biodegradable implant technologies. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. Its products are used worldwide in approximately 40 countries.